Examples of using Bleomycin in English and their translations into Dutch
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Why was Bleomycin reviewed?
Bleomycin, etoposide, and cisplatin?
What? Adriamycin, bleomycin, herceptin?
Bleomycin is intended for the treatment of.
Adriamycin, bleomycin, herceptin.- What?
Bleomycin acts by induction of DNA strand breaks.
Infusion daily for 5 days with bleomycin and etoposide;
In a lower degree bleomycin also affects the RNA and protein synthesis.
And taking into account the current therapeutic use of bleomycin.
In the Netherlands bleomycin is currently approved for the following indications.
Exposure to certain chemicals such as salicylic acid, bleomycin, and cisplatin.
Bleomycin is a cytostatic substance;
The observed toxicity risks are outweighed by the established efficacy of bleomycin.
The efficacy of bleomycin can be considered as established through published literature and current.
5-flurouracil, bleomycin etc. are other options. Complications.
Bleomycin is a nonribosomal peptide that is a hybrid peptide-polyketide natural product.
Questions and answers on the referral for Bleomycin, powder for solution for injection,
Bleomycin inserts itself within the strands of DNA,
fibrosis, which was induced by a chemical bleomycin.
In the combination therapy bleomycin is also of value, even though the evidence of the sole contribution of bleomycin is not assessable.
fibrosis, which was induced by a chemical bleomycin.
The CHMP noted that bleomycin is in clinical use since the 1960ies, thereby explaining the
in vitro systems and animal models of pulmonary fibrosis bleomycin- and transplant-induced fibrosis.
The CHMP also noted that bleomycin is still in use
has completed a referral procedure following a disagreement among Member States of the European Union regarding the authorisation of the medicine Bleomycin injection, from Pharmachemie BV.
Bleomycin belongs to the cytostatic antibiotics:
Pharmachemie BV submitted a Marketing Authorisation Application for Bleomycin powder for solution for injection 15 U/ vial in the decentralised procedure on 10 July 2007, the Netherlands acting as the reference member state.
The effect of bleomycin rests on intercalation with single
Therefore the CHMP is of the opinion that bleomycin is still a valuable chemotherapeutic drug, and adopted the totality of the proposed indications, for Bleomycin Pharmachemie.
The Application for Bleomycin Pharmachemie was submitted as a generic application based on the marketing authorisation granted for the reference product in the Netherlands on 18 November 1997.